A Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®)

Prospective Multi-Center Observational Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA) in the Routine Clinical Settings in the Russian Federation (PETITE)

The objective of this study is to assess persistence, adherence and changes in disease activity in the children population of juvenile arthritis patients treated with adalimumab (HUMIRA®) in the routine clinical settings in the Russian Federation.

Inclusion Criteria:

• Confirmed diagnosis of polyarticular Juvenile Idiopathic Arthritis (JIA) according to International League of Associations for Rheumatology (ILAR) criteria .
• Planned treatment with HUMIRA according to the local product label and prescription guidelines. Alternatively, subjects assigned to HUMIRA treatment not more than 1 month prior to inclusion can be enrolled.
• Negative result of tuberculosis (TB) screening procedure and TB specialist permission to start biologic therapy.
• Patient's informed consent form signed by the parent or guardian/and by the child, if applicable.

Exclusion Criteria:

• Has contraindications for the treatment with HUMIRA according to the latest version of the locally approved label.
• Any biologic drugs taken prior to 3 months of enrolment in the study.
• Patients treated with any biosimilar version of HUMIRA
• Previous participation and dropout from this study.
• Patients participating in another clinical and/or observational study priory 3 months before the enrolment to this study.